贝达药业(300558.SZ)：目前未有贝福替尼和泰瑞西利的全球多中心临床计划

Core Viewpoint - The company has stated that there are currently no global multicenter clinical plans for Beifu Tini and Tairisili, and any significant collaborations or transactions will be disclosed in a timely manner [1] Group 1 - The company is actively engaging with investors through an interactive platform [1] - The company emphasizes transparency regarding major collaborations or transactions [1]